- Pershing Square acquires 2,144,618 shares of Valeant Pharmaceuticals (VRX) from 1-Oct-15 to 23-Nov-15
- Total cost: $240,933,692
- Pershing Square sells strangles to fund purchases of OTM calls; first on 20-Nov-15 and then again on 23-Nov-15
- Total exposure through options: 12,500,000 shares; total cost: $65,561,919
- Total additions: 14,644,618 shares; total cost: $306,495,611
- Pershing Square total stake: 9.9% (34.12 mln shares)
Here’s the latest snippet from a zerohedge post:
- Average cost: $113.76
- Valeant Pharmaceuticals (VRX) current stock price: $87.34 (source: Google Finance; 7:59PM – Nov23’15)
Thanks for reading.
Any opinions expressed herein are solely those of the author, and do not in any way represent the views or opinions of any other person or entity.